INTERVALS: Access The Science Behind Safer Smoking
Philip Morris International (PMI) has shared details of its toxicology data sharing platform INTERVALS at the recent Society of Toxicology Annual Meeting in Baltimore, MD, USA.1 The presentation of INTERVALS, an inhalation toxicology repository for Reduced-Risk Products (RRPs)*, took place during a session hosted by the Institute of In Vitro Sciences exploring best practices and standards in toxicological data sharing. The session was attended by world-leading toxicologists, safety assessment specialists and representatives from the tobacco industry.
“The INTERVALS initiative shows just how seriously PMI is taking the need to have its methodologies and data verified by the external community,” said Dr A. Wallace Hayes, University of South Florida and Michigan State University. “The data are presented in such a way that they are truly accessible, understandable and reusable. What’s also impressive is just how much information is available, everything from the finest details of experimental protocols through to complete, uncensored research datasets. It is my hope that others will take up the challenge by carefully examining the methods and results either to corroborate or refute them. Not only does their approach illustrate the extent to which PMI has changed with regard to openness and transparency, it is also unique within the scientific community in general.”
The INTERVALS proof-of-concept website hosts comprehensive, annotated datasets that have been generated by PMI as part of their development and assessment of RRPs, products with the potential to present less risk of harm to smokers who switch to them as compared to continued cigarette smoking. It has been designed to facilitate the practical reuse of methods and data, and thus to demonstrate the reproducibility of scientific findings. It is hoped that other industries and institutions producing data relevant to RRPs will submit that data to an improved version of the INTERVALS platform to be released at the end of the year for the benefit of the wider community. A comprehensive overview of INTERVALS, describing the rationale for the project and its data practices, has also been published on F1000Research, a transparent publishing platform with no editorial bias, open peer review, and the mandatory inclusion of all source data with submitted papers.2
1. Boué S. 2017. Supporting evidence-based analysis for novel tobacco and alternative products through a toxicology data-sharing infrastructure. IIVS Spotlight: Standards and transparency in toxicology testing. Society of Toxicology Annual Meeting, Baltimore, MD, USA. Wednesday, March 15th.
2. Boué S, et al. 2017. Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure. F1000Research, 6:12 DOI: http://dx.doi.org/10.12688/f1000research.10493.1
This article has been republished from materials provided by INTERVALS. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018